Almost when the New York Times dispatched a long article this weekend on how the pharmaceutical commerce turned “horse estrogen into a billion-dollar panacea for aging women,” the item leapt up on the newspaper’s most e-mailed register — right behind a recipe for oatmeal buttermilk blueberry pancakes.

It stayed there this morning.menopausal hormone therapy

Women taking hormones (and the persons who care about them) should be distributing the item with each other, I thought. That’s good. But the attractiveness of the item furthermore puzzled me.

Are there still any women taking growth hormones for warm blinks, evening worries and vaginal dryness (the only three menopausal “complaints” for which the pharmaceuticals have been verified effective), granted what we understand about the drugs’ long register of wellbeing dangers (blood clots in the lungs, stroke, heart attacks, breast cancerous infection, colon cancerous infection, gall bladder infection and dementia)?

In other phrases, can it be that the data in this item is report to any middle-aged woman?

It seems that it is actually, I shouldn’t be that surprised. For the disease-mongering of menopause continues. Big Pharma appears very resolute to resuscitate the $2-billion-plus (at its heyday) hormone replacement therapy market.

And, regardless of the detail that there are other, safer answers for warm blinks, evening worries and vaginal dryness, hormones extend to be prescribed to women.

Uncovering the disease-mongering
The Times item is partially founded on new court articles got by the bulletin from latest product-liability lawsuits women have conveyed against pharmaceutical manufacturers for overselling the advantages of menopausal hormones and falling short to alert of its risks.

The articles not only display how one pharmaceutical business, Wyeth (maker of Premarin and Prempro) was adept to disperse “like wildfire” the now refuted assertion that menopausal hormone replacement therapy defended the heart from infection, but furthermore how the business (acquired previous this year by the pharmaceutical monster Pfizer) “worked over decades to sustain the likeness and integrity of its hormone pharmaceuticals even as the goods were frequently under siege.”